Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-ANG3 in mixed dyslipidemia
NCT04832971Phase 2Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Aug 2022
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 4
01
Overview
A Phase 2 trial of zodasiran in mixed dyslipidemia, sponsored by Arrowhead Pharmaceuticals. Started Jun 2021; status: completed.
02
Drugs
zodasiran
03
Conditions
mixed dyslipidemia
Beyond the preview
Go deeper on NCT04832971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04832971.